Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 1/20 | 1.00 |
| ▸ | RELA | Q04206 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.90 |
| ▸ | MAPT | P10636 | 5/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 2/20 | 0.82 |
| ▸ | ATM | Q13315 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | HPGD | P15428 | 2/20 | 0.81 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flavokawain C SCHEMBL30384247 | 1.00 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL144231 | 1.00 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL25201341 | 1.00 | NFKB1 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain C SCHEMBL25206856 | 0.99 | NFKB1 (0.97) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain A SCHEMBL2289181 | 0.94 | ABCG2 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain A SCHEMBL2289188 | 0.94 | ABCG2 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain A SCHEMBL29349587 | 0.94 | ABCG2 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| Flavokawain A SCHEMBL25209870 | 0.94 | ABCG2 (1.00) | NFKB1DPP4NFKB2RELAABCG2 | |
| SCHEMBL25200484 | 0.94 | NFKB1 (0.89) | NFKB1DPP4NFKB2RELAABCG2 | |
| SCHEMBL633183 | 0.94 | NFKB1 (0.89) | NFKB1DPP4NFKB2RELAABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2019-02-14 | — | — | US | claimed |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2015-07-30 | — | — | US | claimed |
| WO-2014025989-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | WO | claimed |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | US | claimed |
| WO-2012051107-A2 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE-EFFECT | KUHRTS ERIC HAUSER (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2011-01-06 | — | — | US | claimed |
| US-20090209654-A1 | Prenylflavonoid Formulations | BIOACTIVES, INC. | 2009-08-20 | — | — | US | claimed |
| WO-2008095189-A1 | METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA | BIOACTIVES, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008089137-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1909584-A2 | PRENYLFLAVONOID FORMULATIONS | Bioactives, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20070218155-A1 | Methods and compositions for treating dyslipidaemia | BIOACTIVES, INC. | 2007-09-20 | — | — | US | claimed |
| WO-2007016578-A2 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| WO-2026102866-A1 | USE OF COMBINATION OF FGF-2 AND FLAVOKAWAIN C IN PREPARATION OF DRUG FOR TREATING UTERINE ADHESIONS | 温州医科大学 | 2026-05-21 | — | — | WO | disclosed |
| EP-4734923-A1 | CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS | L'OREAL (FR) | 2026-05-06 | — | — | EP | disclosed |
| EP-1175425-A2 | INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION | THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000043402-A2 | INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2000-07-27 | — | — | WO | disclosed |
| US-4327088-A | ANTIVIRAL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | TP53, CYP46A1, HPGD | NFKB1 590/4885DPP4 3400/4885NFKB2 294/4885 |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | NFKB1 2139/4885DPP4 4002/4885NFKB2 2025/4885 |
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | NFKB1 2139/4885DPP4 4002/4885NFKB2 2025/4885 |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | HMGB2, HMGB3, HPGDS | NFKB1 2092/4885DPP4 2700/4885NFKB2 2036/4885 |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | NAPRT, NISCH, NAMPT | NFKB1 1888/4885DPP4 2758/4885NFKB2 2802/4885 |
| US-20090209654-A1 | Prenylflavonoid Formulations | TP53, CYP46A1, HPGD | NFKB1 590/4885DPP4 3400/4885NFKB2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.